Last reviewed · How we verify
Finerenone 10 MG
At a glance
| Generic name | Finerenone 10 MG |
|---|---|
| Also known as | Kerendia |
| Sponsor | Washington D.C. Veterans Affairs Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Study Comparing the Clinical Benefit of Finerenone Versus a Fixed Dose Combination (FDC) of Extended-Release Torsemide and Spironolactone in Patients With Hypertension and Chronic Kidney Disease (PHASE3)
- Investigation on the Impact of Finerenone on Myocardial Remodeling in Patients With Diabetic Kidney Disease and Heart Failure (PHASE4)
- Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial (PHASE4)
- A Trial to Learn How Well Finerenone Works and How Safe it is in Adult Participants With Non-diabetic Chronic Kidney Disease (PHASE3)
- Efficacy and Safety With Early Treatment of Finerenone in Hospitalized Patients With Heart Failure (PHASE4)
- Finerenone Plus SGLT2 Inhibitors in Heart Failure (PHASE4)
- An Observational Study Called FINEROD to Learn More About the Use of the Treatment Finerenone Including How Safe it is and How Well it Works Under Real-world Conditions
- Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility Study (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Finerenone 10 MG CI brief — competitive landscape report
- Finerenone 10 MG updates RSS · CI watch RSS
- Washington D.C. Veterans Affairs Medical Center portfolio CI